Good morning, Big Story Covaxin, the Covid-19 vaccine developed by Hyderabad-based Bharat Biotech along with ICMR, has demonstrated 81 per cent interim efficacy in phase 3 clinical trials in protecting …
Tag:
Biotechs
-
-
Indian drugmaker Bharat Biotech’s coronavirus vaccine, which has been authorized for use in the country, proved safe and produced an immune response in a small group of adults aged 18 …
-
Days after getting the Drugs Controller General of India’s nod for restricted emergency use of India’s first indigenously-made coronavirus vaccine, Bharat Biotech had applied to the drug regulator for permission …
-
A day after Serum Institute of India’s Covishield was transported to 13 different cities in India from Pune, a consignment of Bharat Biotech’s Covaxin from Hyderabad has landed at the …
-
How did you get into the vaccine business? When I began conceptualising a Hepatitis vaccine, I was working on yeast molecular biology in the US… During that period, there was …
-
India’s drugs regulator has given final emergency-use approval for two coronavirus vaccines — Serum Institute of India’s Covishield, developed by Oxford University and pharma major AstraZeneca, and Bharat Biotech’s Covaxin. …
- News
Coronavirus live: India’s drugs regulator approves Oxford’s COVID-19 vaccine ‘Covishield’ and Bharat Biotech’s ‘Covaxin’ for restricted emergency use
India has approved two COVID-19 vaccines — Serum Institute of India’s ‘Covishield’ and Bharat Biotech’s ‘Covaxin’ — for emergency restricted use, regulatory body DCGI said on Sunday. Both vaccines have …
- News
SEC recommends Bharat Biotech’s COVAXIN for emergency use as India tests its vaccine delivery system – Health News , Firstpost
The recommendation for Bharat Biotech’s vaccine came a day after the COVID-19 expert panel cleared the Serum Institute of India’s emergency use authorisation application for the Oxford-AstraZeneca vaccine ‘Covishield’ A …
-
The Subject Expert Committee of Central Drug Standard Control Organization on Saturday recommended Bharat Biotech’s ‘Covaxin’ for emergency use in India. The final decision on its approval will, however, be …
- News
Bharat Biotech’s phase 1 trial findings show COVID-19 vaccine well tolerated; no serious adverse events
The interim findings of phase 1 clinical trial of COVID-19 vaccine Covaxin, indigenously developed by Bharat Biotech in collaboration with the ICMR, showed that it was was well tolerated in …
- News
COVID-19 vaccine: Bharat Biotech’s Covaxin Phase 1 trial shows it has no serious adverse events
COVID-19 vaccine Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), was well tolerated in all dose groups with no serious or adverse …
